Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500955 · ClinicalTrials.gov registry record · Phase 3
Rosiglitazone on Microalbuminuria in Type 2 Diabetics
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT00500955: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00500955 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 336 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500955, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
Following a 4-week single-blind placebo run-in period, eligible subjects were randomized in a 1:1 ratio to receive 32 weeks of double-blind study medication: Rosiglitazone (starting dose 4mg od) or Glyburide (starting dose 5mg od), both in combination with open-label Metformin \> or = (1g/day). Subjects were stratified for use of ACEI, nondihydropyridine calcium channel blockers (NDP CCB), or angiotensin II receptor blockers (ARB) to provide equal representation of these subjects in each treatment group.
Interventions
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2000-04 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
What the finished NCT00500955 record still lists
NCT00500955 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which Rosiglitazone is the first listed.
NCT00500955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00500955 about?
NCT00500955 is a clinical study titled "Rosiglitazone on Microalbuminuria in Type 2 Diabetics". Following a 4-week single-blind placebo run-in period, eligible subjects were randomized in a 1:1 ratio to receive 32 weeks of double-blind study medication: Rosiglitazone (starting dose 4mg od) or Glyburide (starting dose 5mg od), both in combination with open-label Metformin \> or = (1g/day). Subj...
What is the current status of trial NCT00500955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2000-04. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00500955?
The interventions under investigation include: Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00500955?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00500955's enrollment target sits among peer trials
336 1060th of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia